These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11290864)

  • 1. Granulocyte colony stimulating factors: how different are they? How to make a decision?
    Martin-Christin F
    Anticancer Drugs; 2001 Mar; 12(3):185-91. PubMed ID: 11290864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
    Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
    Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference?
    Höglund M
    Med Oncol; 1998 Dec; 15(4):229-33. PubMed ID: 9951685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colony stimulating factors: G-CSFs--filgrastim (Neupogen) and lenograstim (Granocyte).
    MacConnachie AM
    Intensive Crit Care Nurs; 1998 Feb; 14(1):49-50. PubMed ID: 9652261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of available clinical evidence - filgrastim compared with lenograstim.
    Sourgens H; Lefrère F
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
    Nissen C
    Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®.
    Crobu D; Spinetti G; Schrepfer R; Tonon G; Jotti GS; Onali P; Dedoni S; Orsini G; Di Stefano A
    BMC Pharmacol Toxicol; 2014 Feb; 15():7. PubMed ID: 24555723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
    Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
    Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study.
    Höglund M; Smedmyr B; Bengtsson M; Tötterman TH; Cour-Chabernaud V; Yver A; Simonsson B
    Eur J Haematol; 1997 Sep; 59(3):177-83. PubMed ID: 9310126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
    Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
    Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
    Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells.
    Pedrazzoli P; Gibelli N; Pavesi L; Preti P; Piolini M; Bertolini F; Robustelli della Cuna G
    Anticancer Res; 1996; 16(4A):1781-5. PubMed ID: 8712701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inductive potential of recombinant human granulocyte colony-stimulating factor to mature neutrophils from x-irradiated human peripheral blood hematopoietic progenitor cells.
    Katsumori T; Yoshino H; Hayashi M; Takahashi K; Kashiwakura I
    Biol Pharm Bull; 2009 Nov; 32(11):1849-53. PubMed ID: 19881296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylation interference on RhoA activation: focus on G-CSF.
    Mattii L; Battolla B; Azzarà A; D'Urso G; Montali U; Petrini M
    Leuk Res; 2011 Feb; 35(2):265-7. PubMed ID: 20573400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
    Frampton JE; Yarker YE; Goa KL
    Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.